RPCEC00000014已完成2 期
Clinical trial, phase II. Evaluation of the antitumoral effect of monoclonal antibody h-R3 combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin.
Center of Molecular Immunology(CIM)0 个研究点目标入组 68 人开始时间: 2010年12月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 19 years 至 74 years（—）
- 性别
- All
入选标准
- •1. Patients with non-surgical esophagus tumors of epithelial origin in stages III or IV, located in the following portions of the esophagus: 1- Cervical esophagus: it begins at the lower edge of the cricoid cartilage and ends at the thoracic inlet (suprasternal fossa), 18cm from ICS. 2- Intrathoracic esophagus: a) Upper thoracic portion: from the thoracic inlet (suprasternal fossa) to the trachea bifurcation, 24cm from ICS. b) Middle thoracic segment: it is approximately half of the esophagus, between the trachea bifurcation and the esophagus-gastric join, approximately 32 cm from ICS. 2. Patients without any treatment who are eligible for radio chemotherapy treatment at the time of inclusion. 3. Capacity to understand the study and readiness to sign the informed consent document. 4. Patients with measurable lesions, (in, at least, one dimension: greater diameter) with a diameter greater than or equal to 20mm using conventional techniques (CAT, X rays, US) or greater than or equal to 10mm using helical CAT. 5. Age > 18 and < 75 years. 6. General health condition ECOG < 2 (Karnosfsky > 60%). 7. Life expectancy over 6 months. 8. Patients with organs and bone marrow working normally, defined by the following parameters: leucocytes >3,000/ul, hemoglobin >=9 g/L, absolute neutrophil counting >1,500/ul, platelets >100,000/ul, TGP/TGO 60 ml/min/1.73 m2 for patients with creatinine values higher than normal value, as established by the institution. 9. Reproductive-age females should have a negative pregnancy test and should use appropriate contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation. Males should use contraceptive methods during treatment. 10. Patients who had received appropriate treatment for skin carcinoma or in situ uterus cancer can also be included.
排除标准
- •1. Patients with esophageal tumors in the inferior thoracic portion (distal half of the esophagus, between the tracheal bifurcation and the esophagus-gastric join, approximately 40cm from ICS). 2. Patients on another product under research. 3. Patients with allergy history attributed to chemical or biological compounds similar to TheraCIM h-R3 monoclonal antibody or the chemotherapy used in the study. 4. Patients previously treated with murine monoclonal antibodies (for example, ior egf/r3). 5. Patients with uncontrolled intercurrent diseases, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and psychiatric or social diseases restricting compliance with clinical trial requirements. 6. Breastfeeding should be interrupted after patients are included in the clinical trial, due to potential and unknown adverse events for infants. 7. Patients with previous malignant neoplasias, except patients who received appropriate treatments for skin carcinoma or in situ uterus carcinoma. 8. Patients with brain metastasis.
研究者
相似试验
进行中（未招募）
1 期
Enzalutamide plus Talazoparib for the Treatment of Hormone Sensitive Prostate CancerEUCTR2019-003096-20-ESMedica Scientia Innovation Research S.L. (MEDSIR)54
尚未招募
2 期
Clinical trial of Methotrexate associated to Hydroxyurea versus placebo and Hydroxyurea in patients with sickle cell diseaseRBR-57qbjvCentro Infantil Boldrini
尚未招募
不适用
A phase 2 trial to assess efficacy and safety of Enhertu in HER2-mutant advanced lung cancer patients with asymptomatic brain metastasesNeoplasmsKCT0009147Yonsei University Health System, Severance Hospital27
撤回
2 期
Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 13 substudy 31: EntrectinibCancer - Lung - Non small cellCancer - Any cancerCancerACTRN12621000284864The University of Sydney16
招募中
2 期
Cladribine therapy in MyastheniaMyasthenia gravis2024-517083-32-00Uniwersytet Medyczny W Lublinie200